1. Welcome

3. Dear Tim, as far as I know this is the first patient treated with CAVH in the world. We performed this treatment in Vicenza in 1984 and the patient survived. After that we published the first series of 4 newborns treated with CAVH (Kidney International 1986). You made a great deal of progress since then and even more with this meeting. Best Wishes Claudio Ronco

4. Time and Transition 1984-Ronco’s KI paper 1990-CAVH becomes more common 1993-CVVH with adapted machinery 1995-automated CVVH(D) machinery 1997-ultrafiltration controllers with automated machinery 1998-Acute Dialysis Quality Initiative (ADQI.net) 1999-Thermic controls with automated machinery

5. Time and Transition 2000-1 st International Conference on Pediatric Continuous Renal Replacement Therapy 2001-1 st FDA approved Bicarbonate Based Dialysate (Normocarb) 2001-ppCRRT Registry establishment (Stu Goldstein) 2001-Goldstein data on FO and outcome 2002-Citrate anticoagulation 2002-PCRRT 2 2002-PEDCRRT list serve

6. Time and Transition Gambro releases Prismasate 2003-DiCarlo data on early intervention in Bone Marrow Transplantation 2004-Foland data on FO and outcome 2004-Data emerging on Pharmacy Errors 2004-PCRRT 3 2005-KI paper from ppCRRT 2006 PCRRT-Zurich

7. DIALYSIS MODALITY Belsha et al., Pediatr Nephrol, 1995 Patients (%)

8. Pediatric Choice of RRT # on RRT/yr Year of RRT

9. Why has this become common? Work in vascular access Dedicated staff who is interested in these children Patients continue to be sicker then historically Automated machinery has made the care easier Anticoagulation protocols have made it easier

10. CRRT: Who does it? Outside of NA wide country variation of whom is responsible for this therapy Within NA USA ~ 60% done by Nephrology but often determined by manpower Adult Nephrologists = Adult Intensivists Pediatric Nephrologists < Pediatric Intensivists Canada ~ 50% done by Nephrology

11. Who really does CRRT? Nursing staff of the Dialysis units- thank you Critical Care units- thank you Neonatal intensive Care units- thank you

12. What is the purpose of this meeting? To bring together those in the field who deal with any modality of MOSF with RRT who are willing to listen and learn, to talk and to exchange There are no experts in this field!! “If you quit learning then it is time to go home” (actually he said get the hell out before you hurt someone!) Robert Vernier MD (U of Mn, retired)

13. Thank you To those of you who helped make this meeting happen Faculty Carol Malone Program and Meeting planner-USA Katrin Burow Program and Meeting planner-Europe PCRRT Organizing committee PCRRT Foundation, Inc

14. Who are the faculty? Oskar Baenziger, MD University Children’s Hospital, Zürich, Switzerland Klaus-Eugen Bonzel, MD University Children’s Hospital, Essen, Germany

15. Who are the faculty? Patrick D. Brophy, MD, FRCPC C.S. Mott Children’s Hospital at the University of Michigan, Ann Arbor, Michigan, USA Timothy E. Bunchman, MD DeVos Children’s Hospital, Grand Rapids, Michigan, USA

16. Who are the faculty? Ali Dodge-Khatami, MD, PhD University Children’s Hospital, Zürich, Switzerland Michel Fischbach, MD Hôpital de Hautepierre, Strasbourg, France

17. Who are the faculty? Bernhard Frey, MD University Children’s Hospital, Zürich, Switzerland Andree V. Gardner DeVos Children’s Hospital, Grand Rapids, Michigan, USA

18. Who are the faculty? John J. Gardner, RN DeVos Children’s Hospital, Grand Rapids, Michigan, USA Peter Gessler, MD University Children’s Hospital, Zürich, Switzerland

19. Who are the faculty? Markus J. Kemper, MD University Children’s Hospital Eppendorf, Hamburg, Germany Ernst P. Leumann, MD University Children’s Hospital, Zürich, Switzerland

20. Who are the faculty? Marco Maggiorini, MD University Hospital, Zürich, Switzerland Thomas J. Neuhaus, MD University Children’s Hospital, Zürich, Switzerland

21. Who are the faculty? Ekkehard Ring, MD Medical University Graz, Graz, Austria

22. Thanks to our Supporters-1 Arrow International Baxter Health Care Dialysis Solution Inc Edwards Life Sciences Freseuius Gambro Hospal Janssen-Cilag

23. Novo Nordisk Novartis Pfizer Roche Vicor Government of Zurich (city and county) Swiss parents association of children with kidney disease Thanks to our Supporters-2

24. Who are the Audience 27 abstracts were submitted from 12 separate countries 50% make up of Nursing 45% physician 5% pharmacist

25. A few requests Ask questions.. we all learn Interact with others outside your program during the breaks, lunch Visit the booths learn what each machine, solution, and access can do for your program

26. A few requests Fill out your evaluation cards and hand them into the desk CMEs and CEUs are available for those requesting

27. Finally Have fun and open your mind This is a therapy that is still in development. The applications of these therapies are without boundaries If Carol Malone, Katrin Burow, Thomas Neuhaus, Oskar Baenziger or I can help you in any way, please do not hesitate to ask.

28. Quote that I live by “the smartest one in the room is the child”